Patient was educated on Meloxicam and its mechanism of action as follows:
- Meloxicam is an NSAID that has a preferential role against COX-2 than COX-1.
- COX-2 is mainly produced at the site of inflammation and is responsible for signs and symptoms of inflammation at the site of injury. Inhibition of COX-2, by Meloxicam, at the site of inflammation results in reduced production of prostaglandins.
- Since prostaglandins result in swelling of the injured tissues and amplification of the sensitivity to pain, reduction in the production of prostaglandins by Meloxicam, lead to reduced swelling and decreased sensitivity to pain, which results in pain control.
- COX-1 is mainly located in the GI tract and is more protective on the GI mucosa, preventing the development of gastric ulcers, secondary to NSAID use. Since Meloxicam has little inhibitory effect on COX-1 than COX-2, Meloxicam has mild effect on the GI mucosa and is much easier to tolerate than conventional NSAIDs, such as, Diclofenac Sodium.
- Meloxicam reduces the mild to moderate inflammation in the tissues, by reducing swelling, pain, and temperature.
- Meloxicam is usually used to treat pain of a mild to moderate intensity, such as, arthritis and gout.
